Elevated cerebrospinal fluid kynurenic acid levels in patients with tick-borne encephalitis

Journal of Internal Medicine

Volumn 272, Issue 4, 2012, Pages 394-401

  Holtze, M ^a   Mickiene A ^b,c   Atlas, A ^c   Lindquist, L ^c   Schwieler, L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cognitive symptoms; Immune system; NMDA hypofunction; Tryptophan

Indexed keywords

KYNURENIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PRIORITY JOURNAL; TICK BORNE ENCEPHALITIS;

ADOLESCENT; ADULT; AGED; ENCEPHALITIS, TICK-BORNE; FEMALE; HUMANS; KYNURENIC ACID; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84866330908     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02539.x     Document Type: Article

References (61)

1. Süss J. Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview. Ticks Tick Borne Dis 2011; 2: 2-15.
2. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. Brain 1999; 122: 2067-78.
3. Mickiené A, Laiskonis A, Gunther G, Vene S, Lundkvist A, Lindquist L. Tickborne encephalitis in an area of high endemicity in lithuania: disease severity and long-term prognosis. Clin Infect Dis 2002; 35: 650-8.
4. Haglund M, Forsgren M, Lindh G, Lindquist L. A 10-year follow-up study of tick-borne encephalitis in the Stockholm area and a review of the literature: need for a vaccination strategy. Scand J Infect Dis 1996; 28: 217-24.
5. Haglund M, Gunther G. Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up. Vaccine 2003; 21: 11-8.
6. Karelis G, Bormane A, Logina I et al. Tick-borne encephalitis in Latvia 1973-2009: epidemiology, clinical features and sequelae. Eur J Neurol 2012; 19: 62-8.
7. Růzek D, Salát J, Palus M et al. CD8+ T-cell mediate immunopathology in tick-borne encephalitis. Virology 2009; 384: 1-6.
8. Růzek D, Vancová M, Tesarová M, Ahantarig A, Kopecký J, Grubhoffer L. Morphological changes in human neural cells following tick-borne encephalitis virus infection. J Gen Virol 2009; 90: 1649-58.
9. Isaeva MP, Leonova GN, Kozhemiako VB, Borisevich VG, Maǐstrovskaia OS, Rasskazov VA. Apoptosis as a mechanism for the cytopathic action of tick-borne encephalitis virus. Vopr Virusol 1998; 43: 182-6.
10. Kamalov NI, Novozhilova AP, Kreǐchman GS, Sokolova ED. The morphological characteristics of cell death in different forms of acute tick-borne encephalitis. Morfologiia 1998; 114: 54-8.
11. Gelpi E, Preusser M, Laggner U et al. Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. J Neurovirol 2006; 12: 322-7.
12. Hayaishi O, Yoshida R. Specific induction of pulmonary indoleamine 2, 3-dioxygenase by bacterial lipopolysaccharide. Ciba Found Symp 1978; 65: 199-203.
13. Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364: 82-90.
14. Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 1988; 154: 85-7.
15. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989; 52: 1319-28.
16. Parsons CG, Danysz W, Quack G. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 1997; 283: 1264-75.
17. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001; 21: 7463-73.
18. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 2006; 184: 523-39.
19. Robbins TW, Murphy ER. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci 2006; 27: 141-8.
20. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009; 23: 91-101.
21. Atlas A, Gisslen M, Nordin C, Lindström L, Schwieler L. Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain Behav Immun 2007; 21: 86-91.
22. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001; 313: 96-8.
23. Schwarcz R, Rassoulpour A, Wu HQ et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-30.
24. Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999; 106: 165-81.
25. Holtze M, Asp L, Schwieler L, Karlsson H, Engberg G, Karlsson H. Induction of the kynurenine pathway by neurotropic influenza A virus infection. J Neurosci Res 2008; 86: 3674-83.
26. Pocivavsek A, Wu HQ, Potter MC, Elmer GI, Pellicciari R, Schwarcz R. Fluctuations in endogenous kynurenic Acid control hippocampal glutamate and memory. Neuropsychopharmacology 2011; 36: 2357-67.
27. Potter MC, Elmer GI, Bergeron R et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 2010; 35: 1734-42.
28. Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull 2010; 36: 211-8.
29. Hofmann H, Heinz FX, Dippe H. ELISA for IgM and IgG antibodies against tick-borne encephalitis virus: quantification and standardization of results. Zentralbl Bakteriol Mikrobiol Hyg 1983; 255: 448-55.
30. Nilsson LK, Linderholm KR, Engberg G et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005; 80: 315-22.
31. Heyes MP, Quearry BJ. Quantification of kynurenic acid in cerebrospinal fluid: effects of systemic and central L-kynurenine administration. J Chromatogr 1990; 530: 108-15.
32. Swartz KJ, Matson WR, MacGarvey U, Ryan EA, Beal MF. Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. Anal Biochem 1990; 185: 363-76.
33. Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A 1984; 81: 908-12.
34. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol 2003; 81: 247-65.
35. Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm 2012; 119: 197-209.
36. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002; 196: 459-68.
37. Song H, Park H, Kim YS et al. L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol 2011; 11: 932-8.
38. Pirogova NP, Novitskii VV, Mikhailova OV et al. Cytogenetic disorders in peripheral blood lymphocytes of patients with febrile form of tick-borne encephalitis. Bull Exp Biol Med 2004; 137: 61-3.
39. Liu Z, Dai H, Wan N et al. Suppression of memory CD8+ T cell generation and function by tryptophan catabolism. J Immunol 2007; 178: 4260-6.
40. Gelpi E, Preusser M, Garzuly F et al. Visualization of Central European tick-borne encephalitis infection in fatal human cases. J Neuropathol Exp Neurol 2005; 64: 506-12.
41. Dörrbecker B, Dobler G, Spiegel M, Hufert FT. Tick-borne encephalitis virus and the immune response of the mammalian host. Travel Med Infect Dis 2010; 8: 213-22.
42. Tiszlavicz Z, Németh B, Fülöp F et al. Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 447-55.
43. DiNatale BC, Murray IA, Schroeder JC et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 2010; 115: 89-97.
44. Wang J, Simonavicius N, Wu X et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006; 281: 22021-8.
45. Cosi C, Mannaioni G, Cozzi A et al. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology 2011; 60: 1227-31.
46. Miu J, Ball HJ, Mellor AL, Hunt NH. Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria. Int J Parasitol 2009; 39: 363-70.
47. Rodgers J, Stone TW, Barrett MP, Bradley B, Kennedy PG. Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. Brain 2009; 132: 1259-67.
48. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991; 56: 2007-17.
49. Růžek D, Salát J, Singh SK, Kopecký J. Breakdown of the blood-brain barrier during tick-borne encephalitis in mice is not dependent on CD8+ T-cells. PLoS ONE 2011; 6: e20472. PMID: 21629771.
50. Kondrusik M, Zajkowska J, Pancewicz S, Swierzbińska R, Grygorczuk S, Hermanowska-Szpakowicz T. Interferon gamma concentration in the cerebrospinal fluid of patients with tick-borne encephalitis. Neurol Neurochir Pol 2005; 39: 109-13.
51. Guillemin GJ, Cullen KM, Lim CK et al. Characterization of the kynurenine pathway in human neurons. J Neurosci 2007; 27: 12884-92.
52. Pemberton LA, Kerr SJ, Smythe G, Brew BJ. Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res 1997; 17: 589-95.
53. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, Kalina P. Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes. Neurosignals 2005; 14: 126-35.
54. Olsson SK, Samuelsson M, Saetre P et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci 2010; 35: 195-9.
55. Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G. Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons-possible involvement of endogenous kynurenic acid. Synapse 2006; 59: 290-8.
56. Olsson SK, Andersson AS, Linderholm KR et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol 2009; 12: 501-12.
57. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007; 33: 797-804.
58. Shepard PD, Joy B, Clerkin L, Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003; 28: 1454-62.
59. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004; 56: 255-60.
60. Heyes MP, Saito K, Crowley JS et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992; 115: 1249-73.
61. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011; 25: 561-75.